REGINfo: NOVARTIS - Chimie de spécialité - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
- Remgro
- RICHEMONT
- RMB Holdings
- Sanlam
- Sasol
- Shoprite
- Standard Bank Group
- Tiger Brands
- Vodacom Group
- WOOLWORTHS
> TA 25
Israel - TA 25
- AVNER OIL
- AZRIELI GROUP
- BEZEQ
- DELEK DRILLIN
- DISCOUNT
- ELBIT SYSTEMS
- FIBI BANK
- GAZIT GLOBE
- ICL
- IFF
- ISRAEL CORP
- KENON
- LEUMI
- MIGDAL INSURANCE
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- OSEM
- PAZ OIL
- PERRIGO
- POALIM
- STRAUSS GROUP
- TEVA

Europe

COMPANY SEARCH RESULT

$NOVARTIS: Click to view the issuer\'s details$

Last update : 28/01/2011 >View issuer details

2019.04.30 | 07:15 | Permanent Information Releases / General Company News

puce Sandoz enters agreement for proposed trastuzumab biosimilar, currently in Phase III development, to treat selected HER2-positive cancer tumors - HTML (w)

2019.04.24 | 07:00 | Permanent Information Releases / Sales and Revenues

puce Novartis starts 2019 with strong sales and double digit core[1] operating income growth, Mayzent launch and Alcon spin-off; profit guidance upgraded - HTML (w)

2019.04.24 | 07:00 | Permanent Information Releases / Sales and Revenues

puce Novartis entame 2019 avec une forte croissance des ventes et une hausse à deux chiffres du résultat opérationnel core[1], le lancement de Mayzent et le spin-off d'Alcon; profit annuel revu à la hausse - HTML (w)

2019.04.24 | 07:00 | Permanent Information Releases / Sales and Revenues

puce Novartis startet 2019 mit starken Umsätzen und einer zweistelligen Steigerung des operativen Kernergebnisses[1], Einführung von Mayzent sowie Abspaltung von Alcon; Gewinnprognose angehoben - HTML (w)

2019.04.23 | 13:00 | Permanent Information Releases / Notification of availability

puce Alcon to Host Trading Update for First Quarter 2019 Results - HTML (w)

2019.04.16 | 22:45 | Permanent Information Releases / General Company News

puce AveXis data reinforce effectiveness of Zolgensma® in treating spinal muscular atrophy (SMA) Type 1 - HTML (w)

2019.04.15 | 22:05 | Permanent Information Releases / General Company News

puce Novartis announces FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD - HTML (w)

2019.04.11 | 07:15 | Permanent Information Releases / General Company News

puce Sandoz drives differentiated portfolio with deal to commercialize new treatment for Opioid-Induced Constipation in key European countries - HTML (w)

2019.04.09 | 07:00 | Permanent Information Releases / General Company News

puce Novartis continues transformation into a leading medicines company with completion of the Alcon spin-off - HTML (w)

2019.04.09 | 04:30 | Permanent Information Releases / General Company News

puce Alcon Debuts as Independent, Publicly Traded Company - HTML (w)

2019.04.04 | 22:00 | Permanent Information Releases / General Company News

puce Novartis updates on the migraine collaboration with Amgen - HTML (w)

2019.04.03 | 07:15 | Permanent Information Releases / General Company News

puce Sandoz resubmits biosimilar pegfilgrastim application to US FDA - HTML (w)

2019.04.02 | 07:15 | Permanent Information Releases / General Company News

puce Novartis first-in-class Cosentyx® approved in China for psoriasis patients - HTML (w)

2019.04.01 | 22:05 | Permanent Information Releases / General Company News

puce AveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, Colorado - HTML (w)

2019.04.01 | 07:15 | Permanent Information Releases / General Company News

puce Novartis adds clinical and preclinical anti-inflammatory programs to portfolio with acquisition of IFM Tre - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 1197